Tiny, three-dimensional organoid models are reshaping cancer research by recreating the intricate architecture and diversity of human tumors.

Professor Alexander Hoffmann and Genhong Cheng from University of California, Los Angeles, jointly with Professor David Baltimore from California Institute of Technology, published a review article in the newly launched journal Immunity & Inflammation. This article provides a systematic overview of NF-κB, covering its activation mechanisms, gene regulatory networks, physiological and pathological roles. It also summarizes recent advances in therapeutic strategies targeting NF-κB, offering a critical foundation for deeper understanding the pathway’s functions and mechanisms.

The unfolded protein response (UPR) is a protective pathway that helps cells manage stress during protein production. Cancer cells exploit this system to survive harsh tumor environments. In bones, they also disrupt the balance of bone-building and bone-resorbing cells, leading to skeletal fragility. Emerging therapies that target the UPR show promise in restoring bone health while selectively killing malignant cells, offering new hope for patients with cancer-associated bone disease.

A study coordinated from Badalona by IrsiCaixa, the Catalan Institute of Oncology and the Germans Trias i Pujol Research Institute (within the CARE programme) has identified KIMA, a genomic signature that makes it possible to anticipate which patients with HR+/HER2- breast cancer will respond less well to CDK4/6 inhibitors. The finding, published in the journal Clinical and Translational Medicine, may help personalize therapies and design new combinations.

An international study led by researchers from the Department of Medicine and Life Sciences (MELIS) of Pompeu Fabra University and Stanford University (California) has designed a system to identify highly selective peptides with high therapeutic potential. The method is based on the use of biologically- and chemically-modified bacteriophages to screen, with a high degree of precision, up to 1 billion peptides simultaneously. This allows identifying those that can successfully distinguish very similar proteins that play a significant role in the development of cancer and diabetes, respectively, and that are currently being treated with non-specific drugs.

World's first successful development of innovative nanocomposites comprising lactic acid bacteria components and liquid metal

Selective tumor accumulation via EPR effect with demonstrated visualization and therapeutic efficacy in mouse-transplanted cancers

Complete cancer elimination through synergistic immune activation and photothermal conversion effects under near-infrared light irradiation

Confirmed excellent biocompatibility, promising new cancer diagnostic and therapeutic technologies

A research team from the Anhui Institute of Optics and Fine Mechanics (AIOFM), the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS), in collaboration with the Hefei Cancer Hospital of CAS, has developed a new method to accurately measure hemoglobin levels in blood using near-infrared spectroscopy (NIRS). 

A research team led by Prof. CHU Yannan at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has uncovered a new way to detect cancer early—by analyzing the invisible chemical "scents" that the body gives off.